RESUMO
A broad proteomic analysis was conducted to identify and evaluate candidate biomarkers potentially predictive of response to treatment with an oral selective Janus kinase 1 (JAK1) inhibitor, itacitinib, in acute graft-versus-host disease (GVHD). Plasma samples from 25 participants (identification cohort; NCT02614612) were used to identify novel biomarkers that were tested in a validation cohort from a placebo-controlled, randomised trial (n = 210; NCT03139604). The identification cohort received corticosteroids plus 200 or 300 mg itacitinib once daily. The validation cohort received corticosteroids plus 200 mg itacitinib once daily or placebo. A broad proteomic analysis was conducted using a proximity extension assay. Baseline and longitudinal comparisons were performed with unpaired t-test and one-way analysis of variance used to evaluate biomarker level changes. Seven candidate biomarkers were identified. Monocyte-chemotactic protein (MCP)3, pro-calcitonin/calcitonin (ProCALCA/CALCA), together with a previously identified prognostic acute GVHD biomarker, regenerating islet-derived protein (REG)3A, stratified complete responders from non-responders (participants with progressive disease) to itacitinib, but not placebo, potentially representing predictive biomarkers of itacitinib in acute GVHD. ProCALCA/CALCA, suppressor of tumorigenicity (ST)2, and tumour necrosis factor receptor (TNFR)1 were significantly reduced over time by itacitinib in responders, potentially representing response-to-treatment biomarkers. Novel biomarkers have the potential to identify patients with acute GVHD that may respond to itacitinib plus corticosteroid treatment (NCT02614612; NCT03139604).
Assuntos
Doença Enxerto-Hospedeiro , Transplante de Células-Tronco Hematopoéticas , Acetonitrilas , Doença Aguda , Corticosteroides/uso terapêutico , Biomarcadores , Doença Enxerto-Hospedeiro/tratamento farmacológico , Doença Enxerto-Hospedeiro/etiologia , Transplante de Células-Tronco Hematopoéticas/efeitos adversos , Humanos , Proteômica , Pirazóis , Pirimidinas , PirróisRESUMO
Recent emphasis has focused on the development of rationally designed polymer-based micelle carriers for drug delivery. The current work tests the hypothesis that target specificity can be enhanced by micelles with cancer-specific ligands. In particular, we describe the synthesis and characterization of a new gadolinium texaphyrin (Gd-Tx) complex encapsulated in an IVECT micellar system, stabilized through Fe(III) cross-linking and targeted with multiple copies of a specific ligand for the melanocortin 1 receptor (MC1R), which has been evaluated as a cell-surface marker for melanoma. On the basis of comparative MRI experiments, we have been able to demonstrate that these Gd-Tx micelles are able to target MC1R-expressing xenograft tumors in vitro and in vivo more effectively than various control systems, including untargeted or un-cross-linked Gd-Tx micelles. Taken in concert, the findings reported herein support the conclusion that appropriately designed micelles are able to deliver contrast agent payloads to tumors expressing the MC1R.
Assuntos
Imageamento por Ressonância Magnética/métodos , Micelas , Polímeros/química , Receptor Tipo 1 de Melanocortina/química , Animais , Linhagem Celular Tumoral , Humanos , Camundongos , Camundongos SCIDRESUMO
The incidence of malignant melanoma is rising more rapidly than that of any other cancer in the United States. The melanocortin 1 receptor (MC1R) is overexpressed in most human melanoma metastases, thus making it a promising target for imaging and therapy of melanomas. We have previously reported the development of a peptidomimetic ligand with high specificity and affinity for MC1R. Here, we have conjugated near-infrared fluorescent dyes to the C-terminus of this ligand via lysine-mercaptopropionic acid linkers to generate MC1R specific optical probes (MC1RL-800, 0.4 nM K(i); and MC1RL-Cy5, 0.3 nM K(i)). Internalization of the imaging probe was studied in vitro by fluorescence microscopy using engineered A375/MC1R cells and B16F10 cells with endogenous MC1R expression. The in vivo tumor targeting of MC1RL-800 was evaluated by intravenous injection of probe into nude mice bearing bilateral subcutaneous A375 xenograft tumors with low MC1R expression and engineered A375/MC1R tumors with high receptor expression. Melanotic B16F10 xenografts were also studied. Fluorescence imaging showed that the agent has higher uptake values in tumors with high expression compared to low (p < 0.05), demonstrating the effect of expression levels on image contrast-to-noise. In addition, tumor uptake was significantly blocked by coinjection of excess NDP-α-MSH peptide (p < 0.05). In conclusion, the MC1R-specific imaging probe developed in this study displays excellent potential for the intraoperative detection of regional node involvement and for margin detection during melanoma metastasis resection.
Assuntos
Corantes Fluorescentes/síntese química , Melanoma Experimental/patologia , Proteínas de Neoplasias/análise , Peptidomiméticos/síntese química , Receptor Tipo 1 de Melanocortina/análise , Neoplasias Cutâneas/patologia , Animais , Endocitose/efeitos dos fármacos , Corantes Fluorescentes/metabolismo , Expressão Gênica , Humanos , Injeções Intravenosas , Ligantes , Masculino , Melanoma Experimental/diagnóstico , Melanoma Experimental/genética , Melanoma Experimental/metabolismo , Camundongos , Camundongos Nus , Microscopia de Fluorescência , Imagem Molecular/métodos , Proteínas de Neoplasias/genética , Proteínas de Neoplasias/metabolismo , Peptidomiméticos/metabolismo , Receptor Tipo 1 de Melanocortina/genética , Receptor Tipo 1 de Melanocortina/metabolismo , Neoplasias Cutâneas/diagnóstico , Neoplasias Cutâneas/genética , Neoplasias Cutâneas/metabolismo , alfa-MSH/análogos & derivados , alfa-MSH/farmacologiaRESUMO
PURPOSE: Both photoacoustic tomography (PAT) and fluorescence molecular tomography (FMT) can be used for molecular imaging when contrast agents are administrated. The goal of this work is to comparatively evaluate the performance of reflection-mode PAT and FMT in common phantom when indocyanine green (ICG) was used as a contrast agent. METHODS: Reflection-mode PAT and FMT systems were developed. Target embedded in a background phantom with different ICG concentration, size, and depth location was examined. Comparisons were made in terms of target morphology, spatial resolution, and sensitivity between the two modalities. RESULTS: Phantom results showed that PAT and FMT gave different image morphology. PAT offered higher spatial resolution, while FMT provided higher sensitivity. Thus, improved target detection could be achieved by correlating the complementary information obtained from the two modalities. CONCLUSIONS: The combination of high resolution PAT and high sensitivity FMT will provide a more complete range of pathology spectra for more reliable target detection, suggesting a potentially better diagnostic tool when this combination coupled with the administration of ICG as contrast agent is applied to clinical problems in the future.
Assuntos
Meios de Contraste , Verde de Indocianina , Técnicas Fotoacústicas/métodos , Tomografia/métodos , Imageamento Tridimensional , Imagens de Fantasmas , Espectrometria de FluorescênciaRESUMO
The incidence of malignant melanoma is rising faster than that of any other cancer in the United States. Because of its high expression on the surface of melanomas, MC1R has been investigated as a target for selective imaging and therapeutic agents against melanoma. Eight ligands were screened against cell lines engineered to overexpress MC1R, MC4R, or MC5R. Of these, compound 1 (4-phenylbutyryl-His-dPhe-Arg-Trp-NH(2)) exhibited high (0.2 nM) binding affinity for MC1R and low (high nanomolar) affinities for MC4R and MC5R. Functionalization of the ligand at the C-terminus with an alkyne for use in Cu-catalyzed click chemistry was shown not to affect the binding affinity. Finally, formation of the targeted polymer, as well as the targeted micelle formulation, also resulted in constructs with low nanomolar binding affinity.